GO:0046426 negative regulation of receptor signaling pathway via JAK-STAT: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0046426 describes any process that stops, prevents, or reduces the frequency, rate or extent of a receptor signaling pathway via JAK-STAT [1, 3].
• Negative regulation of JAK-STAT signaling is essential for preventing excessive cytokine responses, autoimmunity, and uncontrolled cell proliferation [1, 5].
• Key negative regulators include SOCS proteins, PTPN2, and viral proteins that target cytokine receptors for degradation [1, 4, 8].
• Dysregulation of this process is linked to autoimmune diseases, cancer, and metabolic disorders such as type 2 diabetes [1, 6, 7].
• CRISPR knockout, point mutation, knock-in, and overexpression models enable precise dissection of negative regulators in this pathway [2, 5].
• Understanding GO:0046426 informs therapeutic strategies targeting JAK-STAT signaling in immuno-oncology and inflammatory diseases [2, 6].
Description
The JAK-STAT pathway is a central signaling cascade that transmits extracellular cytokine and growth factor signals directly to the nucleus, controlling gene expression programs involved in immunity, proliferation, differentiation, and apoptosis. Because excessive or prolonged JAK-STAT activation can drive pathological conditions, cells have evolved multiple layers of negative regulation to terminate or dampen the signal. GO:0046426, negative regulation of receptor signaling pathway via JAK-STAT, captures these inhibitory processes that act on the receptor-proximal steps of the pathway [1, 5]. This term is critical for researchers studying cytokine signaling because it defines the mechanisms that maintain homeostasis and prevent disease. For example, deletion of the phosphatase PTPN2 in B cells leads to hyperactivation of JAK/STAT signaling and autoimmunity, demonstrating the physiological importance of negative regulation. Similarly, viral proteins such as the African swine fever virus p22 promote degradation of the type I interferon receptor to inhibit JAK-STAT signaling, highlighting how pathogens exploit this regulatory node. Understanding GO:0046426 therefore provides a framework for investigating how cells balance activating and inhibitory signals, and how disruption of this balance contributes to human disease.
negative regulation of receptor signaling pathway via JAK-STAT At A Glance
| GO ID | GO:0046426 |
|---|---|
| GO term | negative regulation of receptor signaling pathway via JAK-STAT |
| Ontology | biological_process |
| Synonym | down regulation of JAK-STAT cascade; down-regulation of JAK-STAT cascade; downregulation of JAK-STAT cascade; inhibition of JAK-STAT cascade; negative regulation of STAT protein import into nucleus; negative regulation of STAT protein nuclear translocation |
| Major function | Attenuation or termination of JAK-STAT signaling initiated by cytokine receptors |
| Key negative regulators | SOCS proteins, PTPN2, PTPN1, PIAS proteins, viral inhibitors |
| Associated diseases | Autoimmunity, cancer, type 2 diabetes, viral immune evasion |
| Research methods | CRISPR knockout, RNAi, overexpression, phosphoproteomics, reporter assays |
What Is GO:0046426?
GO:0046426 is a biological process term defined as any process that stops, prevents, or reduces the frequency, rate or extent of a receptor signaling pathway via JAK-STAT. In practical terms, it encompasses molecular events that attenuate or terminate signal transduction initiated by cytokines and growth factors that use Janus kinases (JAKs) and signal transducer and activator of transcription (STAT) proteins. This includes mechanisms such as dephosphorylation of JAKs or STATs, degradation of cytokine receptors, inhibition of STAT nuclear import, and induction of feedback inhibitors like SOCS proteins [1, 5, 8].
Why Is negative regulation of receptor signaling pathway via JAK-STAT Important in Cell Biology?
Negative regulation of JAK-STAT signaling is essential for maintaining immune homeostasis and preventing pathological overactivation. Without proper inhibitory mechanisms, cytokines can drive chronic inflammation, autoimmune responses, and oncogenic transformation [1, 5]. This process also plays a critical role in host-pathogen interactions, as viruses often target JAK-STAT negative regulators to evade immune responses. Furthermore, understanding GO:0046426 has therapeutic implications: modulating negative regulators can enhance or suppress JAK-STAT signaling in diseases ranging from cancer to diabetes [2, 6, 7].
• Prevents excessive cytokine signaling that can lead to autoimmunity and chronic inflammation.
• Controls cell proliferation and survival, with implications for cancer development.
• Regulates immune responses to viral and bacterial infections.
• Influences metabolic homeostasis, including insulin sensitivity and beta-cell function [6, 7].
• Provides targets for therapeutic intervention in inflammatory diseases and cancers.
• Explains mechanisms of viral immune evasion, such as degradation of interferon receptors.
• Essential for normal development and tissue homeostasis.
• Dysregulation is linked to hematological malignancies and solid tumors [1, 5].
• Serves as a paradigm for understanding feedback inhibition in signaling pathways.
• Enables precision medicine approaches by identifying patient-specific regulatory defects.
What Happens During negative regulation of receptor signaling pathway via JAK-STAT?
Receptor Downregulation and Degradation
In simple terms: The cell removes cytokine receptors from its surface so they cannot receive signals.
Negative regulation of JAK-STAT signaling often begins at the receptor level. Ligand-induced internalization and degradation of cytokine receptors reduce the availability of docking sites for JAKs. For instance, the African swine fever virus protein p22 promotes TAX1BP1-mediated degradation of the type I interferon receptor, thereby inhibiting JAK-STAT signaling. Similarly, SOCS proteins can bind to receptor cytoplasmic domains and recruit E3 ubiquitin ligases, leading to receptor ubiquitination and proteasomal degradation.
Inhibition of JAK Kinase Activity
In simple terms: Proteins called phosphatases remove phosphate groups from JAKs, turning off their activity.
JAK kinases are activated by autophosphorylation upon cytokine binding. Negative regulators such as PTPN2 (TC-PTP) and PTPN1 (PTP1B) dephosphorylate JAKs, directly terminating their kinase activity. Deletion of Ptpn2 in B cells results in hyperactivation of JAK/STAT signaling and autoimmunity, underscoring its role as a critical negative regulator. Additionally, SOCS proteins can act as pseudosubstrates or adaptors that inhibit JAK catalytic activity.
Suppression of STAT Phosphorylation and Nuclear Import
In simple terms: The cell blocks STAT proteins from being activated and entering the nucleus.
STAT proteins are phosphorylated by JAKs, leading to dimerization and nuclear translocation. Negative regulation can occur through dephosphorylation of STATs by phosphatases such as PTPN2, or through inhibition of STAT nuclear import. The synonym 'negative regulation of STAT protein import into nucleus' reflects this mechanism. PIAS proteins can also block STAT DNA binding and promote sumoylation, further attenuating the response.
Feedback Inhibition by SOCS Proteins
In simple terms: The cell produces its own inhibitors, like SOCS, that shut down the signal after it starts.
Suppressor of cytokine signaling (SOCS) proteins are induced by JAK-STAT activation and act in a negative feedback loop. SOCS1 and SOCS3 bind to JAKs or cytokine receptors, inhibiting their activity. Drosophila SOCS36E negatively regulates JAK/STAT signaling via two separable mechanisms, demonstrating evolutionary conservation. This feedback ensures transient signaling and prevents sustained activation.
Regulation by Viral and Cellular Inhibitors
In simple terms: Viruses and cells produce proteins that interfere with the JAK-STAT pathway to control it.
Pathogens have evolved proteins that mimic or hijack negative regulatory mechanisms. The African swine fever virus p22 targets the type I interferon receptor for degradation, inhibiting JAK-STAT signaling and evading immune responses. Cellular inhibitors such as PIAS and PTPs also contribute to negative regulation. Combinational silencing of JAK/STAT components can further modulate pathway output, as shown in studies using RNAi.
Key Genes Involved in GO:0046426 negative regulation of receptor signaling pathway via JAK-STAT
The following genes and proteins are key players in the negative regulation of JAK-STAT signaling, based on experimental evidence from the literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PTPN2 | Dephosphorylates JAKs and STATs, terminating signaling | Autoimmunity, cancer, B-cell signaling |
| SOCS1 | Feedback inhibitor of JAK kinase activity | Inflammation, cancer, immune regulation |
| SOCS3 | Binds to cytokine receptors and JAKs to inhibit signaling | Metabolic disease, inflammation |
| PTPN1 | Dephosphorylates JAK2 and other substrates | Diabetes, obesity, cancer |
| PIAS1 | Inhibits STAT DNA binding and promotes sumoylation | Transcription regulation, cancer |
| PIAS3 | Blocks STAT3 activity | Cancer, inflammation |
| CISH | Cytokine-inducible SH2-containing protein, inhibits STAT5 | Immune regulation, cancer |
| TAX1BP1 | Adaptor for receptor degradation | Viral immune evasion |
| USP18 | Deconjugates ISG15, negatively regulates IFN signaling | Antiviral immunity |
| SOCS36E | Drosophila SOCS, negative regulator of JAK/STAT | Developmental signaling |
| IL6R | Cytokine receptor regulated by miR-22 in diabetes | Type 2 diabetes, beta-cell function |
| miR-22 | MicroRNA targeting IL6R and JAK/STAT components | Diabetes, metabolic regulation |
| JAK2 | Kinase subject to negative regulation | Myeloproliferative neoplasms |
| STAT3 | Transcription factor inhibited by negative regulators | Cancer, inflammation |
| STAT5 | Transcription factor inhibited by CISH and SOCS | Hematopoiesis, leukemia |
| PTPRC | CD45 phosphatase, modulates JAK/STAT | Immune cell signaling |
| IFNAR1 | Type I interferon receptor, targeted for degradation | Viral evasion, interferonopathies |
How Is negative regulation of receptor signaling pathway via JAK-STAT Regulated?
Negative regulation of JAK-STAT signaling is itself tightly regulated. SOCS proteins are transcriptionally induced by STATs, creating a negative feedback loop. Phosphatases such as PTPN2 are constitutively expressed but can be modulated by post-translational modifications. Viral proteins like p22 can hijack cellular degradation machinery to downregulate receptors. Additionally, microRNAs such as miR-22 can target components of the pathway, as shown in pancreatic beta-cells. This multilayered regulation ensures appropriate signal duration and intensity.
negative regulation of receptor signaling pathway via JAK-STAT and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PTPN2 | Autoimmunity, B-cell hyperactivation | B-cell-specific knockout mouse |
| SOCS1 | Cancer, inflammation | SOCS1 knockout or overexpression cell lines |
| IL6R | Type 2 diabetes, beta-cell dysfunction | Beta-cell-specific knockout or miR-22 overexpression |
| IFNAR1 | Viral immune evasion | Infection with ASFV p22-expressing virus |
| PIAS1 | Cancer, transcriptional dysregulation | PIAS1 knockout or knockdown in cancer cells |
Autoimmunity and Inflammatory Diseases
Loss of negative regulators such as PTPN2 leads to hyperactive JAK-STAT signaling and autoimmune phenotypes. Deletion of Ptpn2 in B cells promotes autoimmunity via TLR and JAK/STAT signaling. This highlights how impaired negative regulation can break immune tolerance and drive chronic inflammation.
Cancer
Constitutive activation of JAK-STAT signaling is a hallmark of many cancers. Negative regulators like SOCS1 and SOCS3 are often silenced or mutated, leading to uncontrolled proliferation and survival. Understanding GO:0046426 provides insights into tumor suppressor mechanisms and potential therapeutic targets.
Metabolic Disorders
JAK-STAT signaling is implicated in insulin resistance and beta-cell dysfunction. IL6R inhibits viability and apoptosis of pancreatic beta-cells in type 2 diabetes via regulation by miR-22 of the JAK/STAT signaling pathway. Negative regulation of this pathway may therefore influence diabetes progression.
Viral Immune Evasion
Viruses have evolved proteins that mimic negative regulators to suppress host immunity. The African swine fever virus p22 inhibits JAK-STAT signaling by promoting degradation of the type I interferon receptor. This demonstrates how pathogens exploit GO:0046426 to evade antiviral responses.
From negative regulation of receptor signaling pathway via JAK-STAT-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PTPN2 enhance JAK-STAT signaling? | PTPN2 knockout cell line or mouse |
| Can SOCS1 overexpression suppress tumor growth? | SOCS1 overexpression in cancer cell lines |
| How does miR-22 regulate IL6R in beta-cells? | miR-22 mimic/inhibitor in pancreatic beta-cells |
| Does viral p22 target IFNAR1 for degradation? | p22-expressing cell lines or infection models |
| What is the role of PIAS1 in STAT3 DNA binding? | PIAS1 knockout or point mutant |
| Can combinational silencing of JAK/STAT components improve efficacy? | RNAi or CRISPR library screening |
How to Study the negative regulation of receptor signaling pathway via JAK-STAT Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screening | Loss-of-function effects on pathway activity | Identify novel negative regulators [1, 2] |
| Phosphoproteomics | Phosphorylation status of JAKs/STATs | Quantify signaling changes |
| Luciferase reporter assay | STAT transcriptional activity | Screen for inhibitors or regulators |
| Immunofluorescence | STAT nuclear translocation | Visualize negative regulation of import |
| RNAi knockdown | Gene silencing effects | Validate candidate regulators |
| Overexpression | Gain-of-function effects | Test sufficiency of negative regulators |
| Co-immunoprecipitation | Protein-protein interactions | Map SOCS-receptor complexes |
| Flow cytometry | Phospho-STAT levels in single cells | Analyze immune cell signaling |
CRISPR Knockout Screens
Genome-wide CRISPR knockout screens can identify negative regulators of JAK-STAT signaling. Cells with loss of function of candidate genes are challenged with cytokines, and pathway activity is measured by reporter assays or phospho-STAT staining. This approach has been used to uncover novel regulators and validate known ones like PTPN2 [1, 2].
Phosphoproteomics
Mass spectrometry-based phosphoproteomics allows quantitative measurement of phosphorylation events on JAKs, STATs, and receptors. This method can reveal how negative regulators alter the phosphorylation landscape upon cytokine stimulation.
Reporter Assays and Imaging
STAT-responsive luciferase reporters and fluorescently tagged STAT proteins enable real-time monitoring of JAK-STAT activity and nuclear translocation. Imaging can visualize the inhibitory effects of negative regulators on STAT nuclear import.
RNA Interference and Overexpression
RNAi-mediated knockdown or cDNA overexpression of candidate negative regulators can rapidly assess their impact on JAK-STAT signaling. Combinational silencing of multiple components has been used to dissect pathway interactions [2, 7].
How CRISPR Can Be Used to Study GO:0046426 negative regulation of receptor signaling pathway via JAK-STAT
Knockout
CRISPR knockout of negative regulators such as PTPN2 or SOCS1 leads to hyperactivation of JAK-STAT signaling, providing causal evidence for their role in GO:0046426. These models are valuable for studying autoimmunity and cancer [1, 8].
Point Mutation
Introducing point mutations in catalytic domains of phosphatases or in SOCS binding interfaces can dissect specific molecular mechanisms. For example, mutation of the catalytic cysteine in PTPN2 abolishes its phosphatase activity, confirming its role in JAK dephosphorylation.
Knock-in
Knock-in of tagged versions of negative regulators (e.g., GFP-PTPN2) allows real-time tracking of protein localization and interactions. This approach can reveal how these proteins are recruited to activated receptor complexes.
Overexpression
CRISPR activation or cDNA overexpression of negative regulators can suppress JAK-STAT signaling, offering a strategy to counteract pathological activation. Overexpression of SOCS1 or SOCS3 has been shown to inhibit cytokine signaling in various cell types.
How EDITGENE Supports negative regulation of receptor signaling pathway via JAK-STAT Research
Researchers studying negative regulation of receptor signaling pathway via JAK-STAT-related genes often need to determine whether a candidate gene is causally involved in dampening cytokine signaling. This requires precise genetic manipulation to avoid confounding effects from compensatory mechanisms. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such investigations.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of receptor signaling pathway via JAK-STAT research.
Frequently Asked Questions About negative regulation of receptor signaling pathway via JAK-STAT
What is GO:0046426?
GO:0046426 is a Gene Ontology term for any process that stops, prevents, or reduces the frequency, rate or extent of a receptor signaling pathway via JAK-STAT [1, 3].
What genes are involved in negative regulation of JAK-STAT signaling?
Key genes include PTPN2, SOCS1, SOCS3, PTPN1, PIAS1, PIAS3, CISH, and viral factors like ASFV p22 [1, 4, 5, 8].
How does SOCS1 inhibit JAK-STAT signaling?
SOCS1 binds to JAK kinases and inhibits their catalytic activity, acting as a feedback inhibitor induced by STAT activation.
What diseases are linked to defective JAK-STAT negative regulation?
Autoimmune diseases, cancers, type 2 diabetes, and viral immune evasion are associated with dysregulation of this process [1, 4, 6, 7].
What is the role of PTPN2 in JAK-STAT signaling?
PTPN2 dephosphorylates JAKs and STATs, terminating signaling; its deletion leads to hyperactivation and autoimmunity.
How can CRISPR be used to study negative regulation of JAK-STAT signaling?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of negative regulators to assess their impact on pathway activity [2, 5].
What methods measure JAK-STAT negative regulation?
Phosphoproteomics, luciferase reporter assays, immunofluorescence, and flow cytometry are commonly used [4, 5].
Can viruses inhibit JAK-STAT signaling?
Yes, viruses like African swine fever virus express proteins such as p22 that promote degradation of the type I interferon receptor, inhibiting JAK-STAT signaling.
What is the difference between JAK-STAT activation and negative regulation?
Activation initiates signaling via cytokine receptors, while negative regulation attenuates or terminates it through phosphatases, SOCS proteins, and receptor degradation [3, 8].
How does miR-22 regulate JAK-STAT signaling in diabetes?
miR-22 targets IL6R and modulates JAK/STAT signaling, affecting pancreatic beta-cell viability and apoptosis in type 2 diabetes.
Conclusion
GO:0046426, negative regulation of receptor signaling pathway via JAK-STAT, is a fundamental biological process that ensures appropriate control of cytokine signaling. Its dysregulation contributes to autoimmunity, cancer, metabolic disorders, and viral pathogenesis. By leveraging CRISPR-based models and advanced screening technologies, researchers can dissect the molecular players and therapeutic potential of this pathway. EDITGENE offers comprehensive services to support such investigations, from knockout and point mutation models to library screening and bioinformatics.
References
- 1. Alexander BN et al.. 2025. Deletion of Ptpn2 in B cells promotes autoimmunity via TLR and JAK/STAT signaling.. JCI Insight 10(24) PMID: 41424386
- 2. Bousoik E et al.. 2022. Combinational silencing of components involved in JAK/STAT signaling pathway.. Eur J Pharm Sci 175:106233 PMID: 35680032
- 3. Liongue C et al.. 2016. Evolution of Cytokine Receptor Signaling.. J Immunol 197(1):11-8 PMID: 27317733
- 4. Ren H et al.. 2025. The African swine fever virus p22 inhibits the JAK-STAT signaling pathway by promoting the TAX1BP1-mediated degradation of the type I interferon receptor.. PLoS Pathog 21(7):e1013319 PMID: 40668839
- 5. Fisher KH et al.. 2016. Mechanisms of JAK/STAT pathway negative regulation by the short coreceptor Eye Transformer/Latran.. Mol Biol Cell 27(3):434-41 PMID: 26658615
- 6. van Niekerk G et al.. 2021. The immuno-oncological implications of insulin.. Life Sci 264:118716 PMID: 33159956
- 7. Wu X et al.. 2019. IL6R inhibits viability and apoptosis of pancreatic beta-cells in type 2 diabetes mellitus via regulation by miR-22 of the JAK/STAT signaling pathway.. Diabetes Metab Syndr Obes 12:1645-1657 PMID: 31695460
- 8. Stec W et al.. 2013. Drosophila SOCS36E negatively regulates JAK/STAT pathway signaling via two separable mechanisms.. Mol Biol Cell 24(18):3000-9 PMID: 23885117
